2026-06-14T03:32:09Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/165352024-11-29T05:38:17Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16967col_20.500.12105_16982col_20.500.12105_16985col_20.500.12105_16987col_20.500.12105_16988
Repisalud
author
Sastre-Femenia, Miquel Àngel
author
Fernández-Muñoz, Almudena
author
Gomis-Font, María Antonia
author
Taltavull, Biel
author
López-Causapé, Carla
author
Arca-Suárez, Jorge
author
Martínez-Martínez, Luis
author
Cantón, Rafael
author
Larrosa, Nieves
author
Oteo-Iglesias, Jesus
author
Zamorano, Laura
author
Oliver, Antonio
author
GEMARA-SEIMC/CIBERINFEC Pseudomonas study Group
funder
Instituto de Salud Carlos III
funder
Ministerio de Ciencia e Innovación (España)
funder
Unión Europea
2023-10-02T08:56:02Z
2023-10-02T08:56:02Z
2023-11
Lancet Reg Health Eur. 2023 Nov;34:100736.
10.1016/j.lanepe.2023.100736
2666-7762
The Lancet regional health. Europe
https://hdl.handle.net/20.500.13003/19942
37753216
L2027060631
2-s2.0-85171433118
http://hdl.handle.net/20.500.12105/16535
1094639700001
Background: Pseudomonas aeruginosa healthcare-associated infections are one of the top antimicrobial resistance threats world-wide. In order to analyze the current trends, we performed a Spanish nation-wide high-resolution analysis of the susceptibility profiles, the genomic epidemiology and the resistome of P. aeruginosa over a five-year time lapse. Methods: A total of 3.180 nonduplicated P. aeruginosa clinical isolates from two Spanish nation-wide surveys performed in October 2017 and 2022 were analyzed. MICs of 13 antipseudomonals were determined by ISO-EUCAST. Multidrug resistance (MDR)/extensively drug resistance (XDR)/difficult to treat resistance (DTR)/pandrug resistance (PDR) profiles were defined following established criteria. All XDR/DTR isolates were subjected to whole genome sequencing (WGS). Findings: A decrease in resistance to all tested antibiotics, including older and newer antimicrobials, was observed in 2022 vs 2017. Likewise, a major reduction of XDR (15.2% vs 5.9%) and DTR (4.2 vs 2.1%) profiles was evidenced, and even more patent among ICU isolates [XDR (26.0% vs 6.0%) and DTR (8.9% vs 2.6%)] (p < 0.001). The prevalence of Extended-spectrum β-lactamase/carbapenemase production was slightly lower in 2022 (2.1%. vs 3.1%, p = 0.064). However, there was a significant increase in the proportion of carbapenemase production among carbapenem-resistant strains (29.4% vs 18.1%, p = 0.0246). While ST175 was still the most frequent clone among XDR, a slight reduction in its prevalence was noted (35.9% vs 45.5%, p = 0.106) as opposed to ST235 which increased significantly (24.3% vs 12.3%, p = 0.0062). Interpretation: While the generalized decrease in P. aeruginosa resistance, linked to a major reduction in the prevalence of XDR strains, is encouraging, the negative counterpart is the increase in the proportion of XDR strains producing carbapenemases, associated to the significant advance of the concerning world-wide disseminated hypervirulent high-risk clone ST235. Continued high-resolution surveillance, integrating phenotypic and genomic data, is necessary for understanding resistance trends and analyzing the impact of national plans on antimicrobial resistance.
eng
Post-acute sequelae of SARS-CoV-2
PASC
COVID-19
SARS-CoV-2
Electronic health records
Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis
research article
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
URL
https://repisalud.isciii.es/bitstreams/5024401d-7564-4605-911d-16d03860d33e/download
File
MD5
000b1f2d9c0874ad77ea4e284c3ac37f
2154267
application/pdf
PseudomonasAeruginosaAntibioticSusceptibility_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/0d3af3d5-9a58-4161-baae-22503bfa49eb/download
File
MD5
f72bfd14d745057ff1bd1f6b02fb8bb3
312948
application/pdf
TableS1_PseudomonasAeruginosaAntibioticSusceptibility_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/4ace077b-d215-442f-bd50-7003329f53fb/download
File
MD5
0510bb84eec20a38ebcc059fdcb2318b
328789
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet
TableS2_PseudomonasAeruginosaAntibioticSusceptibility_2023.xlsx
URL
https://repisalud.isciii.es/bitstreams/37deeb30-ef85-409d-a5ec-91377b45f47c/download
File
MD5
a0890dc46495e8c1192f39ed2d3b9859
332182
application/pdf
TableS3_PseudomonasAeruginosaAntibioticSusceptibility_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/fcfdc10b-fb9c-4d28-b4f8-d2e0ba3cd0e2/download
File
MD5
19981a6f6ce3472aa00e8e23370ce85f
1479726
application/pdf
Figures_PseudomonasAeruginosaAntibioticSusceptibility_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/d2e413ac-e8e4-4b2b-861c-2a78debe7716/download
File
MD5
8e3e078069183e62853b21e9cb336c1f
58709
text/plain
PseudomonasAeruginosaAntibioticSusceptibility_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/120d2e8b-9c87-4530-ac51-4873c042cd4b/download
File
MD5
10666f942afd0e830693b26ad1d224f3
1903
text/plain
TableS1_PseudomonasAeruginosaAntibioticSusceptibility_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/818e0efb-0280-4847-9f01-d2a75d867e64/download
File
MD5
3d2dac28526d14efbd3bf61e82479647
6902
text/plain
TableS3_PseudomonasAeruginosaAntibioticSusceptibility_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/4d88cffa-b118-4845-94f4-b3463719e5d0/download
File
MD5
a2300027e406d1bf4ec7c5d6aa9fccaa
896
text/plain
Figures_PseudomonasAeruginosaAntibioticSusceptibility_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/a5572e62-7db5-4c6c-a4df-ff8339567438/download
File
MD5
fdf9cbc842e37511b93b85c80025f8bb
101445
text/plain
TableS2_PseudomonasAeruginosaAntibioticSusceptibility_2023.xlsx.txt